Health and Healthcare

Amgen : AMGN

All Amgen Articles

701 Articles

Chris Lange | Nov 28, 2016 at 7:35 AM EST

Short Sellers Grow More Aggressive on Major Biotechs

The November 15 short interest data have been compared with the previous report, and short interest increased in most of…

Lee Jackson | Nov 11, 2016 at 9:35 AM EST

Top Biotech and Health Care Stocks Set to Run on Huge Republican Sweep

With the Republicans now set to control both Congress and the White House, many on Wall Street feel that there…

Chris Lange | Nov 10, 2016 at 7:20 AM EST

Short Sellers Grow More Selective on Major Biotechs

Now that the U.S. presidential election is over and Hillary Clinton is out of the picture, major biotech companies can…

Chris Lange | Oct 29, 2016 at 9:45 AM EDT

6 Companies That Destroyed Shareholders Last Week

The broad markets are holding steady near their double bottom set this summer. However, over the course of the past…

Chris Lange | Oct 28, 2016 at 9:10 AM EDT

Amgen Sinks Despite Beating Street Estimates

Though Amgen reported better-than-expected third-quarter results on Thursday, shares sank early Friday.

Chris Lange | Oct 27, 2016 at 12:40 PM EDT

What to Watch When Amgen Reports Earnings

Biotech giant Amgen is scheduled to release its third-quarter financial results after the markets close on Thursday.

Chris Lange | Oct 26, 2016 at 7:15 AM EDT

Short Sellers Can’t Make Up Their Minds on Major Biotechs

The October 14 short interest data have been compared with the previous report, and short interest moves in these selected…

Chris Lange | Oct 23, 2016 at 10:35 AM EDT

Top Health Care Earnings Coming Next Week

Earnings season is now in full swing, and we have put together a preview of Bristol-Myers, AbbVie and some of…

Jon C. Ogg | Oct 20, 2016 at 12:25 PM EDT

How Just 10 States Saved Almost $120 Billion in 2015 Using Generic Drugs

Americans generally would like to spend less money on health care. One way that this can be and will be…

Lee Jackson | Oct 20, 2016 at 9:55 AM EDT

Mega-Cap Biotechs Cheapest in Years: 4 to Buy for 2017 Gains

These top biotech companies have been absolutely hammered and now trade at a valuation much lower than large cap pharmaceuticals.

Chris Lange | Oct 12, 2016 at 7:10 AM EDT

Short Sellers Have Mixed Views on Major Biotechs

If a single failed clinical trial can mean disaster for a biotech stock, then short sellers can argue for a…

Chris Lange | Sep 27, 2016 at 7:50 AM EDT

Short Sellers Increase Bets in Major Biotechs

The September 15 short interest data have been compared with the previous report, and short interest moves were upward across…

Jon C. Ogg | Sep 26, 2016 at 8:15 AM EDT

How Much Will Consumers Save on New Humira Biosimilar?

In a time when government wrangling about drug prices is more than commonplace, news of a biosimilar for the mega-blockbuster…

Lee Jackson | Sep 19, 2016 at 8:25 AM EDT

RBC Says These 4 Top Biotechs Could Have Big Upside Potential

An RBC report noted that although headline issues such as the Federal Reserve and the election are increasing volatility, four…

Chris Lange | Sep 13, 2016 at 7:05 AM EDT

Short Sellers Run for Cover From Major Biotechs

The August 31 short interest data have been compared with the previous report, and short interest decreased for most of…

1 … 20 21 22 23 24 … 47

Amgen : AMGN

All Amgen Articles

Short Sellers Grow More Aggressive on Major Biotechs

Top Biotech and Health Care Stocks Set to Run on Huge Republican Sweep

Short Sellers Grow More Selective on Major Biotechs

6 Companies That Destroyed Shareholders Last Week

Amgen Sinks Despite Beating Street Estimates

What to Watch When Amgen Reports Earnings

Short Sellers Can’t Make Up Their Minds on Major Biotechs

Top Health Care Earnings Coming Next Week

How Just 10 States Saved Almost $120 Billion in 2015 Using Generic Drugs

Mega-Cap Biotechs Cheapest in Years: 4 to Buy for 2017 Gains

Short Sellers Have Mixed Views on Major Biotechs

Short Sellers Increase Bets in Major Biotechs

How Much Will Consumers Save on New Humira Biosimilar?

RBC Says These 4 Top Biotechs Could Have Big Upside Potential

Short Sellers Run for Cover From Major Biotechs

Why Is Institutional Money Pouring Into XRP ETFs While Fleeing Bitcoin and Ethereum?

U.S. Interest Expense Just Hit $1.6 Trillion Annually. Peter Schiff Warns a Dollar Crisis Arrives When It Hits $2 Trillion.

70-Year-Old Couple With $1.8M Just Got a Stage 2 Cancer Diagnosis. Financial Decisions They Have 60 Days to Make

70-Year-Old Couple With $1.8M Just Got a Stage 2 Cancer Diagnosis. Financial Decisions They Have 60 Days to Make

64-Year-Old Tech Exec Holds $1.6 Million in One Stock. The Wrong Move Could Cost $400,000.

Why Is Institutional Money Pouring Into XRP ETFs While Fleeing Bitcoin and Ethereum?

U.S. Interest Expense Just Hit $1.6 Trillion Annually. Peter Schiff Warns a Dollar Crisis Arrives When It Hits $2 Trillion.

Amgen : AMGN

All Amgen Articles

Short Sellers Grow More Aggressive on Major Biotechs

Top Biotech and Health Care Stocks Set to Run on Huge Republican Sweep

Short Sellers Grow More Selective on Major Biotechs

6 Companies That Destroyed Shareholders Last Week

Amgen Sinks Despite Beating Street Estimates

What to Watch When Amgen Reports Earnings

Short Sellers Can’t Make Up Their Minds on Major Biotechs

Top Health Care Earnings Coming Next Week

How Just 10 States Saved Almost $120 Billion in 2015 Using Generic Drugs

Mega-Cap Biotechs Cheapest in Years: 4 to Buy for 2017 Gains

Short Sellers Have Mixed Views on Major Biotechs

Short Sellers Increase Bets in Major Biotechs

How Much Will Consumers Save on New Humira Biosimilar?

RBC Says These 4 Top Biotechs Could Have Big Upside Potential

Short Sellers Run for Cover From Major Biotechs

Why Is Institutional Money Pouring Into XRP ETFs While Fleeing Bitcoin and Ethereum?

U.S. Interest Expense Just Hit $1.6 Trillion Annually. Peter Schiff Warns a Dollar Crisis Arrives When It Hits $2 Trillion.

70-Year-Old Couple With $1.8M Just Got a Stage 2 Cancer Diagnosis. Financial Decisions They Have 60 Days to Make

Featured Reads

70-Year-Old Couple With $1.8M Just Got a Stage 2 Cancer Diagnosis. Financial Decisions They Have 60 Days to Make

64-Year-Old Tech Exec Holds $1.6 Million in One Stock. The Wrong Move Could Cost $400,000.